Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

Oqory’s planned reverse merger with fellow antibody-drug conjugate (ADC) company Vincerx Pharma has fallen apart at the last ...

When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...

Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after ...

Adagio will now put its resources toward completing the pivotal U.S. trial of its vCLAS catheter and its subsequent marketing ...

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.25 billion ...